224 related articles for article (PubMed ID: 23556336)
1. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
[TBL] [Abstract][Full Text] [Related]
3. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
Yang J; Zhou JS; Tan J; He BS; Zou JJ
Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
6. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
[TBL] [Abstract][Full Text] [Related]
7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.
Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY
Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171
[TBL] [Abstract][Full Text] [Related]
10. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
[TBL] [Abstract][Full Text] [Related]
12. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
[TBL] [Abstract][Full Text] [Related]
16. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.
Yang J; Zhou JS; Zhao YX; Yang ZH; Zhao HD; Zhang YD; Zou JJ
Pharmazie; 2015 Feb; 70(2):97-102. PubMed ID: 25997249
[TBL] [Abstract][Full Text] [Related]
18. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
20. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Wu H; Qian J; Sun A; Wang Q; Ge J
Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
